WuXi AppTec
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Company type | Public |
---|---|
SSE: 603259 | |
Industry | Contract Research Organizations Pharmaceutical Biopharmaceutical Medical Devices |
Founded | 2000 |
Headquarters | Shanghai, China |
Key people | Ge Li |
Website | www |
WuXi AppTec (WuXi is pronounced as Wu-shee) is a global pharmaceutical, biopharmaceutical, and medical device company.
History[edit]
WuXi PharmaTech was founded in December 2000 in Shanghai by organic chemist Ge Li.[1][2]
The company opened chemistry facilities in Tianjin in 2007. In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA. In the same year the company was renamed WuXi AppTec.[3][4] WuXi AppTec opened a toxicology facility in Suzhou in 2009.[5]
WuXi AppTec's subsidiary, WuXi STA, opened a large-scale manufacturing facility in Jinshan in 2010. The company began a biologics discovery, development, and manufacturing operation in Shanghai and Wuxi City in 2011. At the same year, WuXi AppTec acquired MedKey, a China-based clinical research company,[6] and Abgent, a San Diego company and one of the world's largest manufacturers of antibodies for biological research and drug discovery.[7] In 2012, WuXi AppTec opened a chemistry facility in Wuhan and a GMP biologics drug-substance facility in Wuxi City. That year WuXi AppTec also entered into a joint venture with MedImmune, the biologics arm of AstraZeneca, to co-develop MEDI5117, an anti-IL6 antibody for rheumatoid arthritis for the Chinese market.[8] In 2013, WuXi AppTec formed a joint venture with the global clinical contract research organization PRA International (now called PRA Health Sciences) to build a clinical research business in China.[9]
In 2014, WuXi AppTec opened a new biologics biosafety testing facility in Suzhou. In the same year, WuXi AppTec acquired XenoBiotic Laboratories, Inc. (XBL), a contract research organization with 27 years of operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries.[10]
In 2015, the company launched the subsidiary WuXi NextCODE following the acquisition of NextCODE Health, a bioinformatics startup company which emerged from the Icelandic firm deCODE genetics in 2013.[11]
In 2015, WuXi AppTec completed its merger with WuXi Merger Limited, a wholly owned subsidiary of New WuXi Life Science Limited. As a result of the merger, New WuXi Life Science Limited acquired the company in a cash transaction valued at approximately US$3.3 billion.[12] In 2016, WuXi STA opened a new campus in Changzhou[13] and operations in San Diego. In the same year, WuXi AppTec acquired Crelux GmbH, a structure-based drug discovery provider based in Munich, Germany.[14] In 2017, WuXi AppTec acquired HD Biosciences (HDB), a biology focused preclinical drug discovery contract research organization (CRO).[15]
In January 2024, WuXi AppTec's share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns.[16][17][18] The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army (PLA) as a part of the Chinese Communist Party (CCP)'s military-civil fusion strategy.[19] Members of the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party subsequently called for sanctions against WuXi AppTec.[20] WuXi AppTec denied any affiliation with the CCP and PLA and launched a lobbying campaign in the US in response.[21] According to the Federal Bureau of Investigation, United States Department of State, and Director of National Intelligence, WuXi AppTec transferred US intellectual property to the PLA without consent.[22]
References[edit]
- ^ "Company Profile/ leadership". WuXi AppTec. Archived from the original on 15 April 2021. Retrieved 29 March 2021.
- ^ "Company Profile/ History". WuXi AppTec. Archived from the original on 15 April 2021. Retrieved 29 March 2021.
- ^ "Our History". WuXi AppTec. Archived from the original on 22 December 2023. Retrieved 26 December 2023.
- ^ Nagaraj, Amulya; Shen, Samuel (4 January 2008). "WuXi to acquire U.S.-based biopharmaceutical company". reuters.com. Archived from the original on 7 December 2023. Retrieved 3 January 2024.
- ^ "Our History". WuXi AppTec. 29 March 2019. Archived from the original on 17 June 2020. Retrieved 24 June 2020.
- ^ WuXi Acquires Chinese Clinical CROs MedKey and Jiecheng Archived 2022-06-26 at the Wayback Machine 24 October 2011 www.genengnews.com, accessed 28 March 2021
- ^ WuXi PharmaTech Acquires Abgent, a Leading Producer of Biological Research Reagents Archived 2024-03-20 at the Wayback Machine 14 October 2011 www.fiercebiotech.com, accessed 28 March 2021
- ^ MedImmune, WuXi form joint venture Archived 2024-03-20 at the Wayback Machine 10 September 2012 www.biospectrumasia.com, accessed 28 March 2021
- ^ WuXi and PRA form Chinese joint venture Archived 2021-01-11 at the Wayback Machine 8 January 2013 www.pmlive.com, accessed 28 March 2021
- ^ WuXi PharmaTech acquires XenoBiotic Labs Archived 2015-10-24 at the Wayback Machine 1 October 2014 www.thepharmaletter.com, accessed 28 March 2021
- ^ Fidler, Ben (23 October 2013). "DeCode Spinout, NextCode Health, Launches With $15M From Arch, Polaris". Xconomy. Boston. Archived from the original on 27 June 2020. Retrieved 24 June 2020.
- ^ Conyers advises New WuXi Life Science Ltd. in connection with US$3.3 billion buyout Archived 2021-04-14 at the Wayback Machine www.conyers.com, accessed 29 March 2021
- ^ WuXi AppTec's STA Subsidiary Opens New Campus In Changzhou Archived 2022-11-13 at the Wayback Machine 4 March 2016 www.biospace.com, accessed 29 March 2021
- ^ WuXi Apptec acquire Crelux GmbH Archived 2024-03-20 at the Wayback Machine 19 April 2016 biopharma-asia.com, accessed 29 March 2021
- ^ WuXi AppTec acquires HD Biosciences Archived 2021-01-22 at the Wayback Machine 20 January 2017 www.centerwatch.com, accessed 29 March 2021
- ^ "WuXi Bio Denies Military Ties After Shares Slumped on US Bill". Bloomberg News. 2024-01-29. Archived from the original on 2024-01-29. Retrieved 2024-01-30.
- ^ "WuXi AppTec Shares Continue Slide After Company Calls U.S. Draft Bill Findings Inaccurate". The Wall Street Journal. January 28, 2024. Archived from the original on January 29, 2024. Retrieved January 29, 2024.
- ^ "WuXi Company Shares Tumble on U.S. Bill Aimed at Chinese Biotech". The Wall Street Journal. February 2, 2024. Archived from the original on February 1, 2024. Retrieved February 2, 2024.
- ^ Cheung, Sunny; Hope, Arran; Mattis, Peter (February 9, 2024). "Red Genes: Assessing WuXi AppTec's Ties to the Party-Army-State in China". Jamestown Foundation. Archived from the original on 2024-02-10. Retrieved 2024-02-11.
- ^ Martina, Michael (February 12, 2024). "US lawmakers call for sanctions on China's WuXi AppTec biotech firm". Reuters. Retrieved February 12, 2024.
- ^ "Chinese pharma group lobbies against US biotech crackdown". Financial Times. Archived from the original on 2024-03-19. Retrieved 2024-03-20.
- ^ "China's WuXi AppTec shared US client's data with Beijing, US intelligence officials told senators". Reuters. March 28, 2024. Retrieved March 28, 2024.
- ^ WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results
- ^ WuXi PharmaTech Announces First-Quarter 2013
- CanSino Biologics
- CSPC Zhongrun
- China Nepstar
- Fosun Pharmaceutical
- Guangzhou Pharmaceuticals
- Guangyuyuan
- Guizhentang Pharmaceutical Company
- Harbin Pharmaceutical Group
- Hebei Yuxing Bio-Engineering Co. Ltd
- Huadong Medicine
- Jilin Aodong Medicine
- Lijun International Pharmaceutical (Holding) Co. Ltd.
- Kunming Pharmaceutical Corporation
- Nanjing Ange Pharmaceutical
- North China Pharmaceutical Group
- Salubris Pharmaceuticals
- Shanghai Pharmaceuticals Holding Co., Ltd.
- Shenzhen Kangtai Biological Products
- Shijiazhuang Pharma Group
- Sihuan Pharmaceutical
- Simcere Pharmaceutical
- China National Pharmaceutical Group
- Sinovac Biotech
- Tasly
- Tong Ren Tang
- Xiangxue Pharmaceutical
- Yangtze River Pharmaceutical Group
- Yunnan Baiyao Group
- WuXi AppTec
- China Petroleum & Chemical Corporation
- CITIC Securities
- Sany Heavy Industries
- China Merchants Bank
- Poly Real Estate
- China United Network Communications Limited
- TBEA Co., Ltd.
- SAIC Motor
- China Northern Rare Earth
- China CSSC Holdings Limited
- Jiangsu Hengrui Pharmaceuticals
- Wanhua Chemical Group
- NARI Technology
- Zhangzhou Pientzehuang Pharmaceutical
- Tongwei Company
- Kweichow Moutai
- Haier Smart Home
- Shanxi Xinghuacun Fen Wine Factory
- Yili Group
- AECC Aviation Power
- China Yangtze Power
- China Three Gorges Renewables
- LONGi Green Energy Technology
- China Shenhua Energy
- Industrial Bank
- Shaanxi Coal Industry
- Agricultural Bank of China
- Ping An Insurance
- China Railway Group Limited
- Industrial and Commercial Bank of China
- China Pacific Insurance Company
- China Life Insurance
- Great Wall Motor Company
- China State Construction Engineering
- Power Construction Corporation of China
- China Telecom
- PetroChina
- China Tourism Group Duty Free Corporation
- Zijin Mining Group
- Cosco Shipping
- WuXi AppTec
- Foshan Haitian Flavouring & Food Co
- Will Semiconductor
- Zhejiang Huayou Cobalt
- GigaDevice
- Beijing Kingsoft Office Software
- Trina Solar
- Hygon Information Technology
- Semiconductor Manufacturing International Corporation
and
Industry
- CK Hutchison Holdings
- Galaxy Entertainment Group
- MTR Corporation
- Geely Auto
- Alibaba Health
- CITIC Limited
- WH Group
- China Resources Beer
- Orient Overseas (International) Limited
- Tingyi
- Sinopec
- Techtronic Industries
- Tencent
- China Unicom
- PetroChina
- Xinyi Glass
- Zhongsheng Group
- CNOOC Limited
- China Mobile
- Xinyi Solar
- Semiconductor Manufacturing International Corporation
- Lenovo
- Hengan International
- China Shenhua Energy
- CSPC Pharmaceutical Group
- Sinopharm Group
- Sino Biopharmaceutical Limited
- BYD Company
- China Hongqiao Group
- Xiaomi
- Budweiser Brewing Company APAC
- Sands China
- Chow Tai Fook
- Li Auto
- Anta Sports
- WuXi Biologics
- Shenzhou International
- Mengniu Dairy
- Li-Ning
- WuXi AppTec
- Sunny Optical
- Zijin Mining
- Meituan
- Hansoh Pharmaceutical
- JD Health
- Haier
- Haidilao
- JD.com
- Nongfu Spring
- Baidu
- Trip.com Group
- Alibaba Group
- NetEase
- Agricultural Bank of China
- Alibaba Group
- Baidu
- Bank of China
- Bank of Communications
- BYD Company
- CATL
- China Construction Bank
- China Life Insurance Company
- China Merchants Bank
- China Mobile
- China Pacific Insurance Company
- China Shenhua Energy
- CITS Group Corporation
- China Yangtze Power
- CITIC Securities
- CNOOC Limited
- Foshan Haitian Flavouring & Food Co
- Great Wall Motor
- Gree Electric
- Hikvision
- ICBC
- Industrial Bank
- JD.com
- Jiangsu Hengrui Medicine
- Kuaishou
- Kweichow Moutai
- LONGi
- Luxshare
- Meituan
- Midea Group
- Mindray
- Muyuan Foodstuff
- NetEase
- Nongfu Spring
- PetroChina
- Ping An Bank
- Ping An Insurance
- Postal Savings Bank of China
- SF Express
- Shanghai Pudong Development Bank
- Shanxi Xinghuacun Fen Wine Factory
- Sinopec
- Tencent
- Vanke
- Wanhua Chemical Group
- Wuliangye Yibin
- WuXi AppTec
- Xiaomi
- Yihai Kerry